Raphael Pharma launches US proof-of-concept CBG trial for rheumatoid arthritis

Raphael Pharmaceutical Inc.

Proof-of-concept clinical trial begun in US for Cannabigerol (CBG) in active Rheumatoid Arthritis patients.
Engaged MindMate/Citruslabs to oversee trial; estimated timeline 6 months from first participant recruitment.
Trial leverages pre-clinical experiments conducted at Rambam Health Care Campus, Israel.
No financial guidance or material financial impact disclosed in filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.